Natural Alternatives shares rise 10.32% after-hours on improved Q1 results, 13.8% sales growth, and operational profit.

Natural Alternatives International (NAII) surged 10.32% in after-hours trading following the release of its Q1 2026 earnings report, which highlighted a 13.8% year-over-year sales increase to $37.7 million, driven by a 17.7% rise in private-label contract manufacturing revenue. The company narrowed its net loss to $0.3 million ($0.05 per share) from $2.0 million in the prior-year period, with improved gross profit (11.7% margin) and positive operational income of $0.284 million. Management emphasized expanded customer relationships, inventory growth to meet demand, and the potential of its TriBsyn product to capitalize on GLP-1 medication trends. Despite a 33.9% decline in CarnoSyn-related revenue, the guidance for profitability in fiscal 2026’s second half and full-year net income bolstered investor sentiment, aligning with the post-earnings price jump.